Birts, Charles N.
Savva, Constantinos
Laversin, Stéphanie A.
Lefas, Alicia
Krishnan, Jamie
Schapira, Aron
Ashton-Key, Margaret
Crispin, Max
Johnson, Peter W. M.
Blaydes, Jeremy P.
Copson, Ellen
Cutress, Ramsey I.
Beers, Stephen A.
Funding for this research was provided by:
Against Breast Cancer
Cancer Research UK
Breast Cancer Now
World Cancer Research Fund
Article History
Received: 7 December 2021
Accepted: 20 April 2022
First Online: 24 May 2022
Competing interests
: SAB has acted as a consultant for a number of biotech companies and has received institutional support for grants and patents from BioInvent International. Medical body composition analysers provided by SECA as part of an investigator-led Collaborative Research Agreement between Seca GmbH & Co. KG. (Hamburg, Germany), University Hospital Southampton NHS Foundation Trust and the University of Southampton have been utilised by RIC for research purposes. EC has received: honorarium from Astra-Zeneca, Novartis, Pfizer, Roche, Lilly; Advisory boards: Pfizer, Nanostring, Lilly; Expert panel participation: World Cancer Research Fund. RIC and EC report Research funding from SECA and Astra-Zeneca. CNB, CS, SAL, AL, JK, AS, MA, MC, PWMJ, JPB declare no competing interests.